Natriureticpeptides in heart failure Natriuretic peptide drugs represent a significant advancement in the management of cardiovascular conditions, particularly heart failure. These therapeutic agents leverage the body's own natriuretic peptides (NPs), a family of hormones primarily secreted by the heart in response to increased stretch or pressure. Their natural function is to regulate fluid balance, blood pressure, and vascular tone, making them crucial for maintaining cardiovascular homeostasis. The development of drugs based on these peptides offers novel strategies for treating heart failure, a complex condition characterized by the heart's inability to pump blood effectively.
Natriuretic peptides are a class of peptides that play a vital role in regulating the body's fluid and salt balance, as well as blood pressureMetabolic actions of natriuretic peptides and therapeutic .... The primary types of natriuretic peptides include atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP)Natriuretic Peptides in Clinical Practice: A Current Review. ANP is released from the atria of the heart, while BNP is predominantly produced by the ventricles, often in response to increased ventricular wall stress.There are three main types ofnatriuretic peptides: atrialnatriuretic peptide(ANP), brainnatriuretic peptide(BNP), and C-typenatriuretic peptide(CNP). Two ... CNP is found in various tissues, including the vascular endothelium. In conditions like heart failure, levels of these peptides, particularly BNP and its precursor NT-proBNP, are often elevated, serving as important biomarkers for diagnosis and prognosis.
The therapeutic application of natriuretic peptide drugs primarily targets heart failureNatriuretic Peptides. By mimicking or enhancing the effects of endogenous NPs, these drugs aim to alleviate symptoms and improve outcomes for patients.
* Nesiritide: This is a recombinant form of human brain natriuretic peptide (BNP).1天前—TransCon CNP (navepegritide) is an investigational prodrug of C-type natriuretic peptide in development for the treatment of individuals with ... It was one of the earlier natriuretic peptide-based drugs approved for the treatment of acutely decompensated congestive heart failure, particularly in patients experiencing dyspnea at rest. Nesiritide acts by promoting vasodilation, natriuresis (excretion of sodium), and diuresis (increased urine production), thereby reducing cardiac preload and afterload.
* Sacubitril/Valsartan: This combination drug represents a significant breakthrough, being the first approved oral medication in the natriuretic peptide system that targets neprilysinInnovative Therapeutics: Designer Natriuretic Peptides. Sacubitril is a neprilysin inhibitor, which prevents the breakdown of endogenous natriuretic peptides, thereby increasing their levels and enhancing their beneficial effects.2023年12月4日—A BNP test or an NT-proBNP testis mainly used to help diagnose or rule out heart failurein a person who is having symptoms. Valsartan, an angiotensin II receptor blocker (ARB), complements sacubitril's action by blocking the renin-angiotensin-aldosterone system (RAAS), which is often overactivated in heart failure. This dual mechanism makes sacubitril/valsartan highly effective in reducing cardiovascular death and hospitalization in patients with heart failure with reduced ejection fractionNatriuretic peptides(NPs) are involved in the long-term regulation of sodium and water balance, blood volume and arterial pressure..
* Novel and Investigational Agents: Research continues into developing new natriuretic peptide-based therapeutics. This includes designer peptides engineered for specific properties and improved delivery, such as MANP (a novel ANP analog) and TransCon CNP (navepegritide), an investigational prodrug of C-type natriuretic peptide. These novel agents aim to offer enhanced efficacy, improved safety profiles, or different therapeutic targets within the NP pathway.
Natriuretic peptide drugs exert their therapeutic effects through several key mechanisms:
* Vasodilation: They relax blood vessels, reducing resistance against which the heart must pump (afterload) and decreasing the volume of blood returning to the heart (preload).
* Natriuresis and Diuresis: They promote the excretion of sodium and water by the kidneys, helping to reduce overall fluid volume in the body and alleviate edema.
* Inhibition of Neurohormonal Activation: They can counteract the detrimental effects of the sympathetic nervous system and the RAAS, which are often overstimulated in heart failure.
* Cardioprotection: Some NPs have direct protective effects on heart muscle cells.
The primary benefit of these drugs is their ability to improve symptoms of heart failure, such as shortness of breath and fatigue, and to reduce the frequency of hospitalizations due to worsening heart failure作者：HH Chen·2021·被引用次数：45—MANP is a novel ANP (atrial natriuretic peptide) analogengineered to be an innovative particulate GC-A (guanylyl cyclase A) receptor activator.. For drugs like sacubitril/valsartan, long-term use has also been shown to improve survival.
While natriuretic peptide drugs have proven invaluable, their use requires careful patient selection and monitoring. Side effects can include hypotension, dizziness, and renal impairment, especially when combined with other medications. The field of natriuretic peptide therapeutics is dynamic, with ongoing research focused on developing more targeted and effective agents, exploring their potential in other cardiovascular diseases, and refining diagnostic and prognostic applications using natriuretic peptide levels. The integration of these peptide-based therapies into clinical practice continues to evolve, offering renewed hope for patients managing complex cardiovascular conditions.
Join the newsletter to receive news, updates, new products and freebies in your inbox.